Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Alexa B. Kimball's publication output changed over time?
ScholarIQpublication output · 2005–2023
Output grew0% over the shown period — from 1 works in 2005 to 1 in 2023.
1
1
1
1
1
1
1
3
1
1
2005200620072008201020152016201720202023
What are the most-cited papers on Alexa B. Kimball?
ScholarIQmost cited works
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi, Alexa B. Kimball, Kim Papp, Newman Yeilding, Cynthia Guzzo, Yuhua Wang, Shu Li, Lisa T. Dooley, Kenneth B. Gordon
The Lancet. 20081,873 Citations
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Alan Menter, Stephen K. Tyring, Kenneth B. Gordon, Alexa B. Kimball, Craig L. Leonardi, Richard G. Langley, Bruce Strober, Martin Kaul, Yihua Gu, Martin M. Okun, Kim Papp
S58727509. 2007886 Citations
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
Andrew Blauvelt, Kim Papp, C.E.M. Griffiths, B. Randazzo, Yasmine Wasfi, Yaung‐Kaung Shen, Shu Li, Alexa B. Kimball
S58727509. 2017884 CitationsOPEN ACCESS
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Mark Lebwohl, Bruce Strober, Alan Menter, Kenneth B. Gordon, Jolanta Węgłowska, L. Puig, Kim Papp, Lynda Spelman, Darryl Toth, Francisco A. Kerdel, April W. Armstrong, Georg Stingl, Alexa B. Kimball, H. Bachelez, Jashin J. Wu, Jeffrey Crowley, Richard G. Langley, Tomasz Blicharski, C. Paul, J.‐P. Lacour, Stephen K. Tyring, Leon Kircik, Sergio Chimenti, Kristina Callis Duffin, Jerry Bagel, John Koo, Gary Aras, Joanne Li, Wenjie Song, Cassandra E. Milmont, Yifei Shi, Ngozi Erondu, Paul Klekotka, Brian L. Kotzin, Ajay Nirula
New England Journal of Medicine. 2015812 CitationsOPEN ACCESS
Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa
Alexa B. Kimball, Martin M. Okun, David Williams, Alice B. Gottlieb, Kim Papp, Christos C. Zouboulis, April W. Armstrong, Francisco A. Kerdel, Michael H. Gold, Seth Forman, Neil J. Korman, Evangelos J. Giamarellos‐Bourboulis, Jeffrey Crowley, Charles Lynde, Z. Reguiaï, Errol-Prospero Prens, Eihab Alwawi, Nael M. Mostafa, Brett Pinsky, Murali Sundaram, Yihua Gu, Dawn M. Carlson, Gregor B. E. Jemec
New England Journal of Medicine. 2016790 Citations
Related on ScholarIQ
Beth Israel Deaconess Medical Center
Institution
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Paper
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Paper
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
Paper
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Paper
Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa
Paper